SCHEMBL4244111

SCHEMBL4244111

CN(C)c1cccc(F)c1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.48
▸ CES1 P23141 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.47
▸ GAA P10253 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALB P02768 1/20 0.41
▸ PLK1 P53350 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ BCHE P06276 1/20 0.39
▸ TTR P02766 1/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA9 Q16790 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10589172 0.83 CES2 (0.47) CES2CES1TDP1GAAMAPT
SCHEMBL14225316 0.82 TDP1 (0.42) CES2CES1TDP1ALDH1A1KDM4E
SCHEMBL260553 0.79 CES2 (0.67) CES2CES1TDP1ALBBCHE
SCHEMBL8793059 0.78 TDP1 (0.49) TDP1GAAMAPTTSHRALDH1A1
SCHEMBL5317324 0.78 ALDH1A1 (0.53) GAAMAPTTSHRALDH1A1TP53
SCHEMBL11157305 0.77 ALDH1A1 (0.47) GAAMAPTTSHRALDH1A1TP53
SCHEMBL3117223 0.77 CES2 (0.64) CES2CES1TDP1ALBBCHE
Hydrochloric Acid SCHEMBL7968059 0.77 CES2 (0.64) CES2CES1TDP1ALBBCHE
SCHEMBL10414139 0.76 BID (0.45) GAAMAPTTSHRALDH1A1TP53
SCHEMBL7690206 0.74 MAPT (0.46) CES2CES1TDP1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 — — US disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, MTNR1A CES2 3766/4885CES1 2183/4885TDP1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback